Navigation Links
Regeneron Announces Appointment of Robert E. Landry as Senior Vice President, Finance and Chief Financial Officer
Date:9/10/2013

TARRYTOWN, N.Y., Sept. 10, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the appointment of Robert E. Landry as Senior Vice President, Finance.  Mr. Landry will also assume the position of Chief Financial Officer of Regeneron on October 1.  After 18 years as CFO, Murray A. Goldberg will transition to a new role as Senior Vice President, Administration in anticipation of his retirement at the end of 2014.

Mr. Landry brings over two decades of varied financial and operating experience in the global pharmaceutical industry, most recently as Senior Vice President and Treasurer of Pfizer, Inc.  He will report to Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  Mr. Landry will have responsibility for all financial functions, including Controller's, Treasury, Financial Planning, Tax, and Internal Audit.  In his new role, Mr. Goldberg will continue to have responsibility for Alliance Management and various administrative functions.

"Murray has been an integral member of the Regeneron senior management team for close to two decades and his contribution to our success as we grew from a development stage biotechnology company to one of the largest biotechnology companies in the world has been invaluable.  We are extremely fortunate that Murray will stay at Regeneron through 2014 to help us with the transition to a new CFO," said Dr. Schleifer.  "Bob Landry brings with him a breadth of domestic and international financial expertise at Pfizer and Wyeth.  We look forward to the valuable perspective he will bring, as we continue to expand our operations in the U.S. and globally."

"I am pleased to be able to join
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Regenerons Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentechs Lucentis
2. Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS
3. Regeneron Reports Second Quarter 2013 Financial and Operating Results
4. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
5. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
6. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
7. Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
8. Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013
9. Regeneron Pharmaceuticals Announces Expansion in New Yorks Hudson Valley
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015 Bloomage BioTechnology Corporation ... a strategic cooperation with the South Korean BioTech Company ... joint venture Medybloom to develop and promote Type A ... . Medytox, the Botulinum Toxin ... is also the fourth company in the world successfully ...
(Date:7/27/2015)... , July 27, 2015 Varian Medical Systems ... National Health Service to equip and service two new national ... with the Varian ProBeam ® proton therapy system. Earlier ... preferred supplier for two three-room NHS centers to be constructed ... . Varian expects to book the equipment portion of ...
(Date:7/27/2015)... 2015 EMD Millipore , the ... of Darmstadt, Germany , today ... pegylation services to customers developing protein-based therapeutics and ... collaboration includes feasibility studies, process and analytical development, ... for pilot and subsequent commercial scale. ...
Breaking Medicine Technology:Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3Varian Signs Contracts to Equip Two National Proton Therapy Centers in England 2Varian Signs Contracts to Equip Two National Proton Therapy Centers in England 3Varian Signs Contracts to Equip Two National Proton Therapy Centers in England 4EMD Millipore Adds Protein Pegylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH 2EMD Millipore Adds Protein Pegylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH 3
... (Nasdaq: PDEX ) today announced its financial results for ... addition, Pro-Dex announced that its existing credit agreement with Wells ... hired, a product development agreement was signed with a new ... developed product. , Sales for the first quarter ended September ...
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) ... company, today announced they have entered into an exclusive ... Australia and New Zealand. An intravenous formulation of ibuprofen, ... the hospital setting. Cumberland Pharmaceuticals received U.S. Food and ...
Cached Medicine Technology:PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 2PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 3PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 4PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 5PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 6PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 7PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 8PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 9PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 10Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 2Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 3Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 4Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 5
(Date:7/27/2015)... ... July 27, 2015 , ... ... **FDAnews Webinar**, Aug. 13, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... first things FDA investigators will look at during an inspection. Yet, in ...
(Date:7/27/2015)... ... July 27, 2015 , ... Looking to brush up on all the things ... of New Jersey has enhanced its Dental webpage with new materials, including user-friendly, educational ... , “Horizon is committed to offering our 3.8 million members tools and resources to ...
(Date:7/27/2015)... ... July 27, 2015 , ... Send Word ... and mobile collaboration, announced today the latest software release for its ... other feature enhancements. , This software release gives the widely used online application ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ongoing ... to its options. Already an industry leader because of its use of ... for the latest successful trends in helping people to overcome addiction and live ...
(Date:7/27/2015)... Plains, NJ (PRWEB) , ... July 27, 2015 , ... ... New Jersey. Dr. Breslow is Founder and Medical Director of The Breslow Center ... for the face, breast, and body in Northern New Jersey. The Breslow Center ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:Thinking about a Dental Check-up? Check out Horizon Blue Cross Blue Shield of New Jersey’s Enhanced Website for a Dental Download of Helpful Information 2Health News:Send Word Now Announces Release of New User Interface for its Award-Winning Mass Notification Service 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3Health News:NJ Top Doc, Dr. Gary Breslow, has launched Zwivel; a New Online Cosmetic Consultation Service for Doctors and Patients 2
... News) -- Researchers have identified three gene abnormalities that ... cancer, with one in particular -- the PTEN gene ... Dr. Charis Eng, founding director of the Genomic Medicine ... a news release that her team,s "investigation into the ...
... , Countries recovering from war are at risk of being ... leaving an "open door" for exploitation by alcohol, tobacco and ... Bulletin of the World Health Organization, Bayard Roberts and ... Medicine, and Preeti Patel, of King,s College London, argue that ...
... By Randy Dotinga HealthDay Reporter , FRIDAY, Dec. ... percent of New York City residents may be at risk of ... be a major culprit. The research has major limitations: ... daily lives or physically track their activities. Even so, the study,s ...
... FRIDAY, Dec. 30 (HealthDay News) -- New research suggests that ... multiple sclerosis also damages the part of the brain that ... thalamus is a central area that relates to the rest ... co-author Khader Hasan, an associate professor at University of Texas ...
... 30 (HealthDay News) --,Binge drinking can be contagious between romantic ... 208 unmarried heterosexual dating couples in their early 20s who ... least one member of each couple was a university or ... of three months and an average of close to two ...
... Dec. 29 (HealthDay News) -- There are many ways to ... the easiest ways is also one of the most important: ... holidays when people travel and get together for parties and ... and Safety noted. "Hand-washing is the single most effective ...
Cached Medicine News:Health News:Gene Mutations Linked to Thyroid Cancer Risk: Study 2Health News:New report highlights need for action on health in the aftermath of war 2Health News:MP3 Players May Be Major Source of Hearing Loss 2Health News:MP3 Players May Be Major Source of Hearing Loss 3Health News:Multiple Sclerosis May Cause Changes in Thalamus: Study 2Health News:Hand-Washing Key to Stopping Spread of Disease 2
... Endoscopic CycloPhotocoagulation (ECP) is a surgical approach ... and visualized laser application. The ciliary body ... the surgeon, from the anterior or posterior ... The target tissues are easily and accurately ...
... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... surgical approach to glaucoma management that employs ... ciliary body (which produces aqueous humour) is ... or posterior segment, through the endoscope in ... and accurately identified utilizing endoscopy. This allows ...
... Endoscopic CycloPhotocoagulation (ECP) is a surgical ... endoscopy and visualized laser application. The ciliary ... by the surgeon, from the anterior or ... time. The target tissues are easily and ...
Medicine Products: